After a significant drop in biotech IPOs in 2025, this year is seeing a revival, largely driven by advancements in AI. Experts highlight that AI is reshaping biotechnology investment by offering better risk assessment and program optimization for drug development. Companies like Eikon Therapeutics, Aktis Oncology, and Generate:Biomedicines are successfully leveraging AI to bolster their pitches to investors, showcasing the technology as a core component of their business models. With substantial IPO raises, there is a renewed optimism in the sector, with analysts suggesting that AI could become integral to biotech’s future success.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.biospace.com/business/biotech-ipos-rebound-as-ai-takes-a-more-central-role-in-drug-development
